Current Headlines

31. New Thesis Shows Methods To Map Shared Genetics And Uncover Clues For Drug Development 4/2/2026

    Many common diseases and other complex traits, such as heart disease, diabetes, and psychiatric disorders, are influenced by a very large number of genetic variants, each with only a small effect.

32. BioXcel Therapeutics Announces Food & Drug Administration Acceptance Of Supplemental New Drug Application For Use Of IGALMI® In The At-Home Setting 4/1/2026

    BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia.

33. UNC Research Contributes To FDA Approval Of New Drug For Rare Genetic Disorder 4/1/2026

    A drug tested in a clinical trial at UNC, led by renowned UNC pediatric biochemical geneticist Joseph Muenzer, MD, PhD, has been approved by the U.S. Food and Drug Administration.

34. Flagship Pioneering And AWS Announce Collaboration To Accelerate Drug Discovery And Life Sciences Innovation 4/1/2026

    Flagship Pioneering, a scientific innovation engine for transformative platforms and products, and Amazon Web Services (AWS) today announced a strategic collaboration to accelerate the development and scaling of breakthrough life sciences companies.

35. Cogent Biosciences Announces Submission Of New Drug Application For Bezuclastinib In Gastrointestinal Stromal Tumors (GIST) 4/1/2026

    Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib.

36. Quantum Biopharma Submits Investigational New Drug (IND) Application To United States Food And Drug Administration (FDA) For Lucid-MS Phase Two Clinical Trial In Multiple Sclerosis 4/1/2026

    Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has formally submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Lucid-21-302 (Lucid-MS), its new drug candidate for the treatment of multiple sclerosis (MS).

37. NJ Bio, Inc. And Ajinomoto Bio Pharma Services Enter Into Collaboration To Strengthen Support For Antibody-Drug Conjugate Development 3/31/2026

    NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies, today announced a research collaboration to expand access to AJICAP™, Aji Bio‑Pharma's site‑specific conjugation platform for NJ Bio's discovery‑stage and early development clients.

38. Lupin Receives Tentative Approval From U.S. FDA For Sugammadex Injection 3/31/2026

    Global pharma major, Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial.

39. OpenProtein.AI Expands Strategic Partnership With Boehringer Ingelheim To Advance AI-Driven Antibody Discovery 3/31/2026

    OpenProtein.AI, a leader in AI-powered protein engineering software, today announced an expansion of its partnership with Boehringer Ingelheim to co-develop specialized antibody discovery and optimization workflows.

40. Asha Therapeutics Launches As First Atom Therapeutics, A Zero-Shot De Novo Drug Design Company 3/30/2026

    Asha Therapeutics has announced its rebranding as First Atom Therapeutics (“First Atom”), marking the company’s evolution as a zero-shot de novo drug design company using AI-enabled molecular design technology to create transformative medicines for neurodegenerative, neuro-oncological, and rare diseases.